Clinical Intelligence

Janssen’s Nucynta meets primary endpoint in diabetic peripheral neuropathy study

Monday, May 21, 2012 02:46 PM

Janssen Pharmaceuticals has issued results from an investigational phase III study suggesting Nucynta ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy (DPN).

More... »

Pharmos' levotofisopam trial in gout earns positive results

Friday, May 18, 2012 12:52 PM

Pharmos, a biopharmaceutical company based in Iselin, N.J., has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

More... »

City of Hope finds potential cure for type 1 diabetes

Friday, May 18, 2012 10:11 AM

City of Hope, a research, treatment and education center for cancer, diabetes and other life-threatening diseases based in Duarte, Calif., has developed a combination therapy to treat late-stage type 1 diabetes (T1D) that appears to offer a potential lifetime cure for the disease without toxic side effects. The laboratory study was published in the May 9, 2012, edition of Science Translational Medicine.

More... »

Elevation Pharma releases positive phase IIb results in COPD

Thursday, May 17, 2012 10:31 AM

Elevation Pharmaceuticals, a San Diego-based company focused on the development of new aerosol therapies, has released positive results from a phase IIb study of EP-101 in patients with chronic obstructive pulmonary disease (COPD), a progressive disease of chronic bronchitis and emphysema.

More... »

Achillion receives Fast Track for Hep C drug

Thursday, May 17, 2012 10:15 AM

The FDA has granted Fast Track designation to Achillion Pharmaceuticals’ ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV).

More... »

The CenterWatch Monthly, May 2012

Tuesday, May 1, 2012 08:00 AM

Newer sites most optimistic about the future

More... »

Baxter reports positive phase III results for Gammagard Liquid

Monday, April 30, 2012 04:02 PM

Baxter International, a healthcare company based in Deerfield, Ill., has released results from its phase III clinical trial evaluating Gammagard Liquid 10% (Immune Globulin Infusion (Human)) for the treatment of multifocal motor neuropathy (MMN).

More... »

FDA approves Stendra for ED

Monday, April 30, 2012 03:45 PM

The FDA has approved Stendra (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S., according to biopharmaceutical company Vivus.

More... »

Actelion's macitentan meets primary endpoint in phase III PAH study

Monday, April 30, 2012 12:10 PM

Switzerland-based Actelion Pharmaceuticals' initial analysis indicates that the pivotal, long-term phase III SERAPHIN study with macitentan, a novel dual endothelin receptor antagonist, has met its primary endpoint.

More... »

Pharmanest initiates phase I SHACT trial

Monday, April 30, 2012 11:45 AM

Pharmanest, a Stockholm-based pharmaceutical company, has dosed its first patient has in an open label pharmacokinetic phase I study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.

More... »